Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function
PSMA-RLT is an effective and safe treatment in mCRPC patients with preexisting impaired renal function (CTCAE ≥2). In daily clinical practice, patients should not be categorically excluded from enrolment to PSMA-RLT due to renal impairment.
Authors
- Caroline Burgard (ORCID: https://orcid.org/0000-0003-1522-8860)
- Arne Blickle (ORCID: https://orcid.org/0009-0009-2460-7249)
- Samer Ezziddin (ORCID: https://orcid.org/0000-0003-4110-3375)
- Sven Petto
- Maike Sieben
- Mark Bartholomä (ORCID: https://orcid.org/0000-0002-0361-2833)
- Stephan Maus (ORCID: https://orcid.org/0000-0002-5131-526X)
- Moritz B. Bastian
- Andrea Schaefer-Schuler (ORCID: https://orcid.org/0000-0002-2439-5786)
- Florian Rosar (ORCID: https://orcid.org/0000-0002-2985-4099)
- Tilman Speicher
Institutions
- All-Russian State Scientific Research Institute for Control, Standardization and Certification of Veterinary Preparations (RU)
- The Patients Association (GB)
- Saarland University (DE)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1097/rlu.0000000000005583
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51